Le Lézard
Classified in: Health
Subjects: NPT, STP, AVO

Petition filed by Three Nonprofit Groups Asking FTC to Investigate Maine Dental Board for Antitrust Violation

AUGUSTA, Maine, Oct. 31, 2019 /PRNewswire/ -- Three national nonprofits have petitioned the Federal Trade Commission (FTC) to investigate the Maine Board of Dental Practice for antitrust violations. According to the petition, https://tinyurl.com/FTC-MEdentalboard, the dental board refuses to enforce the state's fact sheet law. As a result, some dentists who still use dental amalgam are withholding information from patients about amalgam's mercury content.

Consumers for Dental Choice, Organic Consumers Association and Mercury Policy Project state in their petition that the Maine board engages in a variety of actions1 to evade enforcing the state law requiring every dentist who uses amalgam to give patients a state-approved fact sheet. 

"The Maine Dental Board is not above the law," said Katherine Paul of Freeport, Maine, speaking for Organic Consumers Association. "As with any other state agency, the board must support, enforce and adhere to the law." If this board doesn't want to fulfill its duty, Maine's Governor should appoint a new dental board."

"The behavior of the Maine dental board raises serious antitrust questions because the board is protecting the income of the pro-mercury dentists," said Charles Brown of Consumers for Dental Choice and a former antitrust law specialist. "This board must redirect its loyalty from protecting sales of amalgam to protecting Maine's families and consumers."  

"Dental amalgam is a major mercury pollution source worldwide resulting from its continuing use in Maine and elsewhere," said Michael Bender of the Mercury Policy Project.   "Consumers must be told that amalgam is mainly mercury, but also that there are nonmercury alternatives available that work just as well or better."

The petitioners note that use of the term "silver fillings" instead of "amalgam" deceives patients.

1 For example, the dental board advises dentists that compliance with the mandate is optional (although it is required), and the board held a secret vote to ally with the Maine Dental Association to defeat a state law that would shift MaineCare to mercury-free dentistry. The dental board has proposed a rule regarding disclosure, but it fails even to mention the Maine fact sheet law or the official fact sheet, which was written by then Director of Health Dora Mills.

--Katherine Paul, Organic Consumers Ass'n, katherine@organicconsumers.org, 207.653.3090
--Charles Brown, Consumers for Dental Choice, charlie@mercury-free.org, 202.544.6333
--Michael Bender, Mercury Policy Project, mercurypolicy@aol.com, 802.917.8222      

SOURCE Consumers for Dental Choice

These press releases may also interest you

at 20:57
The Salt River Pima-Maricopa Indian Community ("SRPMIC") has awarded a grant of $50,000 to the Veterans Medical Leadership Council (VMLC), through their 12% Gaming Grant Program. The VMLC supports Veterans of any era who have a verified and bonified...

at 20:36
Thermo Fisher Scientific Inc. ("Thermo Fisher") announced today that it has priced an offering of $5.85 billion aggregate principal amount (the "Offering") of the following notes, each issued at par: $1,000,000,000 aggregate principal amount of its...

at 20:26
Molecular Lab Partners LLC, a national provider of turn-key Physician Office Laboratory (POL) Solutions, announced strong growth during the third quarter of 2021. The company achieved 86% revenue growth during the quarter.  The growth is reflective...

at 20:00
The sexual wellness market is expected to grow by USD 32.02 billion from 2021-2025, progressing at a CAGR of 10.86% according to the latest market report by Technavio....

at 19:45
Heart to Heart Hospice, a leader in hospice services since 2003, will soon be opening a new Hospice Inpatient Center in Houston. The facility is located inside Proveer at Northgate (formerly Pathways Memory Care) at 2930 Cypress Grove Meadows Drive....

at 19:35
Merck , known as MSD outside the United States and Canada, is voluntarily recalling one lot of CUBICIN® (daptomycin for injection) 500 mg for intravenous use, Lot 934778, Exp June 2022. Because treatment with CUBICIN is likely to be initiated at a...

News published on 31 october 2019 at 08:03 and distributed by: